Compare ZD & NTLA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ZD | NTLA |
|---|---|---|
| Founded | 1995 | 2014 |
| Country | United States | United States |
| Employees | 3900 | 377 |
| Industry | Advertising | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 1.6B |
| IPO Year | 1999 | 2016 |
| Metric | ZD | NTLA |
|---|---|---|
| Price | $43.50 | $13.49 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 7 | 20 |
| Target Price | ★ $39.71 | $20.45 |
| AVG Volume (30 Days) | 729.4K | ★ 3.0M |
| Earning Date | 05-07-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 27.43 |
| EPS | ★ 1.15 | N/A |
| Revenue | ★ $1,364,028,000.00 | $67,671,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $2.16 | $62.75 |
| P/E Ratio | $38.49 | ★ N/A |
| Revenue Growth | N/A | ★ 16.92 |
| 52 Week Low | $22.45 | $6.73 |
| 52 Week High | $50.55 | $28.24 |
| Indicator | ZD | NTLA |
|---|---|---|
| Relative Strength Index (RSI) | 60.76 | 51.57 |
| Support Level | $34.96 | $12.55 |
| Resistance Level | $45.26 | $14.32 |
| Average True Range (ATR) | 1.98 | 0.76 |
| MACD | -0.18 | 0.07 |
| Stochastic Oscillator | 60.93 | 60.80 |
Ziff Davis Inc is a digital media and internet company operating a portfolio of brands across technology, shopping, gaming and entertainment, health and wellness, connectivity, and cybersecurity. The company has five reportable segments. The Technology & Shopping segment generates revenue from advertising and commerce content. The Gaming & Entertainment segment provides content, subscriptions, and digital storefront services. The Health & Wellness segment offers digital tools and content for health management. The Connectivity segment provides data and analytics solutions for network performance. The Cybersecurity & Martech segment delivers cloud-based software for security and marketing. It generates the majority of its revenue from the Health & Wellness segment.
Intellia Therapeutics is a gene-editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It's evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis.